Stevanato Group (STVN)
(Delayed Data from NYSE)
$18.60 USD
-0.02 (-0.11%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $18.69 +0.09 (0.48%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth B Momentum F VGM
Stevanato Group (STVN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$27.75 | $37.00 | $21.00 | 49.03% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Stevanato Group comes to $27.75. The forecasts range from a low of $21.00 to a high of $37.00. The average price target represents an increase of 49.03% from the last closing price of $18.62.
Analyst Price Targets (8 )
Broker Rating
Stevanato Group currently has an average brokerage recommendation (ABR) of 1.60 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.60 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, seven are Strong Buy, representing 70% of all recommendations. A month ago, Strong Buy represented 70%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 7 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.60 | 1.60 | 1.60 | 1.60 | 1.60 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/7/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/7/2024 | UBS | John N Sourbeer | Hold | Hold |
7/2/2024 | KeyBanc Capital Markets | Paul Knight | Strong Buy | Strong Buy |
6/27/2024 | William Blair | Matt Larew | Strong Buy | Strong Buy |
5/10/2024 | Not Identified | Not Identified | Hold | Hold |
4/22/2024 | Exane BNP Paribas | Research Department | Not Available | Strong Buy |
3/25/2024 | Stephens | Jacob Johnson | Strong Buy | Strong Buy |
9/19/2023 | CJS Securities | Lawrence S Solow | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.60 |
ABR (Last week) | 1.60 |
# of Recs in ABR | 10 |
Average Target Price | $27.75 |
LT Growth Rate | 7.00% |
Industry | Medical - Drugs |
Industry Rank by ABR | 96 of 253 |
Current Quarter EPS Est: | 0.13 |